MedTrace Logo

PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept

NCT00527072 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2012-09-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least four months, without enough improvement in their psoriasis symptoms.

Conditions

Interventions

BIOLOGICAL

infliximab

Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.

Sponsors & Collaborators

  • Centocor Ortho Biotech Services, L.L.C.

    lead INDUSTRY

Principal Investigators

  • Centocor Ortho Biotech Services, L.L.C. Clinical Trial · Centocor Ortho Biotech Services, L.L.C.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-05-31
Completion
2009-10-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00527072 on ClinicalTrials.gov